Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clinica BavieraXMAD:CBAV -0.70%100 3-Year Dividend Growth Rate is 15.10% as of Jun. 2026, which is 17% below its 10-year median of 18.10. GuruFocus rates XMAD:CBAV with a GF Score™ of 100/100 and a GF Value™ of €44.74 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 49 Medical Diagnostics & Research companies, Clinica Baviera ranks better than 61.22% on this metric.
The historical rank and industry rank for Clinica Baviera's 3-Year Dividend Growth Rate or its related term are showing as below:
XMAD:CBAV'
s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -26.8 Med: 18.1 Max: 47.4
Current: 15.1
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Clinica Baviera was 47.40% per year. The lowest was -26.80% per year. And the median was 18.10% per year.
XMAD:CBAV's 3-Year Dividend Growth Rate is ranked better than 61.22% of 49
companies
in the Medical Diagnostics & Research industry
Industry Median: 10.1
vs XMAD:CBAV: 15.10
During the past 12 months, Clinica Baviera's average Dividends Per Share Growth Rate was -50.00% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 15.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
During the past 13 years, the highest Dividend Payout Ratio of Clinica Baviera was 0.74. The lowest was 0.36. And the median was 0.63.
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
Clinica Baviera Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
EUR 1.570000
2026-06-10
2026-06-11
2026-06-12
Cash Dividend
annually
EUR:EUR 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Clinica Baviera's Dividend Yield (%) for Today is calculated as
Current Share Price is €56.40.
Clinica Baviera's Dividends per Share for the trailing twelve months (TTM) ended in Today is €1.57.
During the past 13 years, the highest Dividend Yield of Clinica Baviera was 7.44%. The lowest was 1.55%. And the median was 4.02%.
Warning Sign:
Clinica Baviera SA stock Dividend Yield % is close to 5-year low.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinica Baviera 3-Year Dividend Growth Rate Related Terms>
XMAD:CBAV vs TMO, DHR, NTRA: 3-Year Dividend Growth Rate Comparison
For the Diagnostics & Research subindustry, Clinica Baviera's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinica Baviera 3-Year Dividend Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Clinica Baviera's 3-Year Dividend Growth Rate distribution charts can be found below:
* The bar in red indicates where Clinica Baviera's 3-Year Dividend Growth Rate falls into.
This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Dividend Growth Rate of 15.10% mean?
Clinica Baviera (XMAD:CBAV) has a 3-Year Dividend Growth Rate of 15.10% as of Jun. 2026. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Clinica Baviera and its competitors. This is 17% below median its historical median of 18.10. According to the industry distribution chart, Clinica Baviera ranks #19 out of 49 companies in the Medical Diagnostics & Research industry, placing it in the top 38.8%.
Is Clinica Baviera's 3-Year Dividend Growth Rate too high?
Clinica Baviera's current 3-Year Dividend Growth Rate of 15.10% is 17% below median its 10-year median of 18.10. The Medical Diagnostics & Research industry median 3-Year Dividend Growth Rate is 10.10. Clinica Baviera's value of 15.10% is 49.5% above this industry median. Based on the distribution chart, Clinica Baviera ranks #19 out of 49 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Clinica Baviera has a GF Score™ of 100/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clinica Baviera's 3-Year Dividend Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Clinica Baviera ranks #19 out of 49 companies for 3-Year Dividend Growth Rate. This puts Clinica Baviera in the upper half of its industry. The industry median 3-Year Dividend Growth Rate is 10.10. Clinica Baviera's value of 15.10% is 49.5% above this benchmark. While the company's 10-year median is 18.10 vs. the industry median of 10.10, Clinica Baviera has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Dividend Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year Dividend Growth Rate among Medical Diagnostics & Research companies is 10.10, based on 49 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Dividend Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Dividend Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinica Baviera's current 3-Year Dividend Growth Rate of 15.10% is 49.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Dividend Growth Rate mean?
A high 3-Year Dividend Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Clinica Baviera and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year Dividend Growth Rate is 10.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinica Baviera's current 3-Year Dividend Growth Rate is 15.10%, which is 17% below median its own 10-year median of 18.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinica Baviera stock overvalued right now?
Based on GuruFocus' analysis, Clinica Baviera (XMAD:CBAV) is currently considered Modestly Overvalued. The stock's GF Value™ is €44.74, compared to a current price of €56.40 — trading 26.1% above its estimated fair value. The current 3-Year Dividend Growth Rate is 15.10%, which is 17% below median its 10-year median of 18.10 and 49.5% above the Medical Diagnostics & Research industry median of 10.10. Clinica Baviera's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Dividend Growth Rate calculated?
3-Year Dividend Growth Rate is calculated from a company's financial statements. For Clinica Baviera (XMAD:CBAV), the current 3-Year Dividend Growth Rate is 15.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinica Baviera (XMAD:CBAV) Overvalued in 2026?
Based on GuruFocus' analysis, Clinica Baviera stock appears to be overvalued.
The current stock price of €56.40 is trading 26.1% above its estimated GF Value™ of €44.74.
GuruFocus considers Clinica Baviera to be Modestly Overvalued.
Key valuation signals for XMAD:CBAV:
3-Year Dividend Growth Rate: 15.10% (17% below median its 10-year median of 18.10)
GF Value™: €44.74 vs. price of €56.40 (26.1% above fair value)
Industry Position: 49.5% above the Medical Diagnostics & Research median (#19 of 49)
No single metric tells the full story. See the XMAD:CBAV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinica Baviera SA operates ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. It offers diagnosis and treatment for various eye problems such as long-sightedness, short-sightedness, astigmatism, cataracts and eye strain.
100GF Score
Get the complete analysis for XMAD:CBAV
3-Year Dividend Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:CBAV has been successfully added to your 
